The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: A pilot study

Liver International

Volumn 29, Issue 2, 2009, Pages 169-174

  Tandon, Puneeta ^a   Tsuyuki, Ross T ^a   Mitchell, Lesley ^a   Hoskinson, Michael ^a   Ma, Mang M ^a   Wong, Winnie W ^a   Mason, Andrew L ^a   Gutfreund, Klaus ^a   Bain, Vincent G ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Albumin; Ascites; Hepatorenal syndrome; Midodrine; Octreotide; Refractory ascites

Indexed keywords

ALBUMIN; ALDOSTERONE; DIURETIC AGENT; MIDODRINE; OCTREOTIDE; RENIN;

ADULT; ARTICLE; ASCITES; BRAIN DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG INTERMITTENT THERAPY; FEMALE; HEPATORENAL SYNDROME; HUMAN; KIDNEY FUNCTION; LIVER FAILURE; LONG TERM CARE; LOW DRUG DOSE; MALE; NATRIURESIS; OPTIMAL DRUG DOSE; PARACENTESIS; PILOT STUDY; RECURRENT DISEASE; RISK REDUCTION; SCORING SYSTEM; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREND STUDY;

ALBERTA; ALBUMINS; ALDOSTERONE; ANALYSIS OF VARIANCE; ASCITES; CREATINE; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MIDODRINE; OCTREOTIDE; PILOT PROJECTS; PROSPECTIVE STUDIES; RADIOIMMUNOASSAY; RADIOISOTOPE RENOGRAPHY; RENIN;

EID: 58149496630     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01778.x     Document Type: Article

References (26)

1. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164-76.
2. Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: Report of the consensus conference of the International Ascites Club. Hepatology 2003; 38: 258-66.
3. Moller S, Henriksen JH. Neurohormonal fluid regulation in chronic liver disease. Scand J Clin Lab Invest 1998; 58: 361-72.
4. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-7.
5. Campbell MS, Brensinger CM, Sanyal AJ, et al. Quality of life in refractory ascites: Transjugular intrahepatic portal-systemic shunting versus medical therapy. Hepatology 2005; 42: 635-40.
6. Saab S, Nieto JM, Lewis SK, et al. TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Collab 2006; 4: 004889.
7. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: A retrospective multicenter study. Gastroenterology 2002; 122: 923-30.
8. Solanki P, Chawla A, Garg R, et al. Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003; 18: 152-6.
9. Sanyal A, Boyer T, Garcia-Tsao G, et al. A prospective, randomized, double-blind placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Hepatology 2006; 44: 694A.
10. Gluud LL, Kjaer MS, Christensen E. Terlipressin for hepatorenal syndrome: A cochrane systematic review. Cochrane Database Syst Rev 2006; 4: 005162.
11. Ottesen LH, Aagaard NK, Kiszka-Kanowitz M, et al. Effects of a long-acting formulation of octreotide on renal function and renal sodium handling in cirrhotic patients with portal hypertension: A randomized, double-blind, controlled trial. Hepatology 2001; 34: 471-7.
12. Sanyal AJ. Octreotide and its effects on portal circulation. Gastroenterology 2001; 120: 303-5.
13. Angeli P, Volpin R, Piovan D, et al. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology 1998; 28: 937-43.
14. Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study. Hepatology 2002; 36: 941-8.
15. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
16. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999; 130: 461-70.
17. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Am J Kidney Dis 2002; 39 (Suppl. 1): S1.
18. Kalambokis G, Fotopoulos A, Economou M, et al. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites. J Hepatol 2007; 46: 213-21.
19. Gentilini P, Casini-Raggi V, Di Fiore G, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: Results of a randomized controlled trial. J Hepatol 1999; 30: 639-45.
20. Schindler C, Ramadori G. Albumin substitution improves urinary sodium excretion and diuresis in patients with liver cirrhosis and refractory ascites. J Hepatol 1999; 31: 1132.
21. Kalambokis G, Fotopoulos A, Economou M, et al. Octreotide in the treatment of refractory ascites of cirrhosis. Scand J Gastroenterol 2006; 41: 118-21.
22. Angeli P, Volpin R, Gerunda G, et al. Reversal of Type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 1690-7.
23. Kalambokis G, Economou M, Fotopoulos A, et al. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal function in nonazotemic cirrhotic patients with ascites. Am J Gastroenterol 2005; 100: 879-85.
24. Mastai R, Bosch J, Navasa M, et al. Effects of alpha-adrenergic stimulation and beta-adrenergic blockade on azygos blood flow and splanchnic haemodynamics in patients with cirrhosis. J Hepatol 1987; 4: 71-9.
25. Albillos A, Lledo JL, Rossi I, et al. Continuous prazosin administration in cirrhotic patients: Effects on portal hemodynamics and on liver and renal function. Gastroenterology 1995; 109: 1257-65.
26. Alessandria C, Ottobrelli A, Debernardi-Venon W, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: A prospective, randomized, unblinded, pilot study. J Hepatol 2007; 47: 499-505.